Beyond respiratory disease, antagonists of TMEM16A have been proposed to have utility in treating a wide variety of other diseases including, pulmonary hypertension (Namkung et al., 2010; Forrest et al., 2012; Heinze et al., 2014), secretory diarrhea (Ousingsawat et al., 2011; Thiagarajah et al., 2015), polycystic kidney disease (Buchholz et al., 2014), pain (Cho et al., 2012; Lee et al., 2014; Pineda-Farias et al., 2015) and cancer. This evidence concerns the gene ANO1 and respiratory system disorder.